Abstract
BackgroundThe current standard of care for recurrent/metastatic squamous cell carcinoma of head and neck (SCCHN) includes immune checkpoint inhibitors, which have demonstrated survival benefit. However, overall response rate remains around...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
